Original Source: Orthopedic Devices Market

Buy Now: Market Research

Dallas, TX: ReportsandReports announce it will carry Italy Orthopedic Devices Market Outlook to 2016 Market Research Report in its Store.

GlobalData’s medical equipment report, “Italy Orthopedic Devices Market Outlook to 2016” provides key market data on the Italy orthopedic devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories - Orthobiologics, Joint Reconstruction, Spinal Surgery, Trauma Fixation, Arthroscopy, Orthopedic Accessories, and Orthopedic Braces and Supports. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

• Market size and company share data for seven orthopedic devices market categories - Orthobiologics, Joint Reconstruction, Spinal Surgery, Trauma Fixation, Arthroscopy, Orthopedic Accessories, and Orthopedic Braces and Supports.
• Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within seven market categories. Data from 2002 to 2009, forecast forward for 7 years to 2016.
• 2009 company shares and distribution shares data for each of the seven market categories.
• Global corporate-level profiles of key companies operating within the Italy orthopedic devices market.
• Key players covered include DePuy, Stryker, Zimmer, Synthes, Medtronic, Smith & Nephew and Biomet.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Italy orthopedic devices competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Browse complete report: Italy Orthopedic Devices Market Outlook to 2016

Browse all Medical Devices Market Research Reports

Browse all GlobalData Market Research Reports

Browse all Italy Market Research Reports

Browse all Newly Published Market Research Reports

Related Reports:


Belgium Orthopedic Devices Market Outlook to 2016

Argentina Orthopedic Devices Market Outlook to 2016

Mexico Orthopedic Devices Market Outlook to 2016

Republic of Korea Orthopedic Devices Market Outlook to 2016

Taiwan Orthopedic Devices Market Outlook to 2016

About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/

Dallas, TX: ReportsandReports announce it will carry Italy In Vitro Diagnostics Market Outlook to 2016 Market Research Report in its Store.

GlobalData’s new report, “Italy In Vitro Diagnostics Market Outlook to 2016” provides key market data on the Italy In Vitro Diagnostics (IVD) market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories – clinical chemistry, genetic testing, histology and cytology, immuno chemistry, infectious immunology, microbiology culture, and haematology. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Browse all Medical Devices Market Research Reports

Browse all GlobalData Market Research Reports

Browse all Newly Published Market Research Reports

Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004

Website: http://www.reportsandreports.com/

Blog: http://reportsnreports.wordpress.com/

Blog: http://reportsandreports.blogspot.com/

Browse the complete Report on: Italy Oil and Gas Report 2010
Browse All Business Monitor International Market Research Reports

BMI forecasts that Italy will account for 12.43% of Developed European regional oil demand by 2014, while contributing 4.04% to supply. In Developed Europe, overall oil consumption was an estimated 13.28mn barrels per day (b/d) in 2009. It is set to recover to around 13.44mn b/d by 2014. Developed Europe regional oil production was 6.96mn b/d in 2001, and in 2009 averaged an estimated 4.73mn b/d. It is set to fall to just 3.71mn b/d by 2014. Oil imports are growing steadily because supply is contracting and demand is rising, albeit slowly. In 2009, net crude imports were an estimated 9.18mn b/d. By 2014, they are expected to have reached 9.73mn b/d. Norway will remain the only major net exporter, with the UK a net importer.
As regards natural gas, the Developed Europe region in 2009 consumed an estimated 426bn cubic metres (bcm), with demand of 473bcm targeted for 2014, representing 9.6% growth. Production of an estimated 265bcm in 2009 is set to fall to 263bcm in 2014, which implies net imports rising from the estimated 2009 level of 161bcm to some 210bcm by the end of the period. Italy’s share of gas consumption in 2009 was an estimated 17.83%, while it contributed around 3.21% to production. By 2014, its share of gas consumption is forecast to be 18.01%, with a 3.04% contribution to regional supply.
We are sticking with our forecast that the OPEC basket of crudes will average US$83.00/bbl in 2010. Wide variations in crude differentials so far in 2010 make forecasting tricky for Brent, West Texas Intermediate (WTI) and Urals, but we believe the three benchmarks will average around US$85.11, US$88.22 and US$83.62/bbl respectively, with Dubai coming in at US$83.14. By 2011, there should be further growth in oil consumption and more room for OPEC to regain market share and reduce surplus capacity through higher production quotas. We are assuming a further increase in the OPEC basket price to an average US$85.00/bbl. For 2012 and beyond, we continue to use a central case forecast of US$90.00/bbl for the OPEC basket.
For 2010, the BMI assumption for premium unleaded gasoline is an average global price of US$96.83/bbl. The year-on-year (y-o-y) rise in 2010 gasoline prices is put at 38%. Gasoil in 2010 is expected to average US$92.45/bbl, with the full-year outturn representing a 37% increase from the 2009 level. For jet fuel in 2010, the annual level is forecast to be US$95.58/bbl. This compares with US$70.66/bbl in 2009. The 2010 average naphtha price is put by BMI at US$82.46/bbl, up 39% from the previous year’s level.
Italian real GDP is assumed by BMI to have fallen by 4.5% in 2009, followed by forecast growth of 0.7% in 2010. We are assuming 1.5% average annual growth in 2010-2014. By 2014, we expect to see the country consuming 1.67mn b/d of oil. A rise in near-term domestic oil production is expected. We are assuming oil production of 165,000b/d in 2010, but imports are set to reach 1.52mn b/d by 2014. Use of gas in power generation is the key to demand growth and consumption looks set to reach 85.1bcm by 2014. Imports are likely to have reached 77.1bcm at this stage.
Between 2010 and 2019, we are forecasting a decrease in Italian oil production of 33.3%, with output peaking at 170,000b/d in 2011 before slipping to 110,000b/d at the end of the 10-year forecast period. Given oil consumption is forecast to increase by 1.53%, imports can also be expected to rise from an estimated 1.47mn b/d in 2010 to 1.55mn b/d by the end of the forecast period. Gas demand should rise from the estimated 2010 level of 77.5bcm to 94.0bcm by 2019. Production of an estimated 8.5bcm in 2010 is expected to fall to 6.0bcm by 2019, requiring imports up from 69.0bcm to 88.0bcm, in the form of pipeline gas and LNG. Details of BMI’s 10-year forecasts can be found in the appendix to this report. According to BMI’s country risk team, Italy’s long-term political risk score is 80.3, compared with the Developed Markets average of 86.7 and the global average of 63.7. Our long-term economic rating for the country is 64.6, below the Developed Markets average of 67.0 and above the global average of 53.7. Italy has a privatised energy sector operating under EU guidelines. There is a significant upstream oil and gas segment featuring domestic and foreign operators. Downstream oil is highly competitive and involves a mixture of international oil companies (IOCs) and domestic companies. Both the gas and power markets are privatised and open to competition.


About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.


Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://reportsandreports.blogspot.com/
http://reportsandreports.proarticles.co.uk/
http://reportsnreports.wordpress.com/

Original Source : Oil and Gas Market


Buy Now : Market Research Report

Browse the complete Report on : Italy Pharmaceuticals and Healthcare Report Q4 2010

Browse All Business Monitor International Market Research Reports

In BMI's Q410 Pharmaceuticals & Healthcare Business Environment Ratings (BERs), the Western Europe region scored a total of 64.5 out of 100. The attractiveness of the region to pharmaceutical firms stems from the fact that its countries are key revenue sources for 'big pharma', particularly for companies selling high-end products, as per-capita spending is substantially above that of emerging markets. However, it is BMI's view that drug companies will face many challenges in Western Europe over the next decade, including pressures to reduce fiscal deficits, the patent cliff, added regulatory hurdles and increasingly scrupulous cost-effectiveness assessments of new drugs – all factors that will influence the risk and reward scores assigned to markets in the region.
In the Q410 BERs, Italy remains the least attractive Western European market of the ten surveyed. Despite being a large market, Italy is characterised by low levels of growth, largely a result of widespread price cuts and shaky levels of economic growth – which translate into insufficient funds for pharmaceutical expenditure, especially for innovative products. High levels of public debt, poor infrastructure and a lack of competitiveness indicate that the country will remain one of the region’s laggards over our forecast period. Additionally, pharmaceutical companies’ performance in the country – already hampered by counterfeiting and parallel imports – is also expected to be majorly impacted by the pending patent expiration ‘slope’.
In July 2010, Silvio Berlusconi's government won a confidence vote in the Senate over its EUR25bn (US$32bn) austerity package aimed at lowering the country's budget deficit from 5.3% of GDP in 2009 to 2.7% by 2012. The package incorporated a series of relatively minor changes introduced by parliament since the bill was originally presented at the end of May 2010.
Included in the package are a number of medicine cost-containment plans, as well as moves to speed the introduction of electronic prescribing, which in turn is expected to increase the prescription of generic medicines. Furthermore, a reduction in margins on sales of Class A reimbursed drugs will be split between pharmacists and manufacturers, with pharmacists losing 1.82% and drugmakers 1.83%. Furthermore, aiming to make annual savings of at least EUR600mn (US$768mn), the Italian agency for pharmaceuticals (AIFA) is to review the pharmaceutical expenditure of the various territorial regions in Italy in order to provide 'tools' that will direct the prescription of medicines towards lower-cost generic drugs.
Additionally, in a bid to contain rising healthcare costs and an increasing state drugs bill, the maximum reimbursement rate paid for generic medicines by the Italian national health service (SSN) will be based on the drugs' average prices in Europe as of 2011. The government claims pricing drugs in this manner will create cost savings of EUR600mn (US$768mn). Hitting generic drug producer revenues more immediately is a 12.5% reduction on retail prices of generics, an initiative implemented in June 2010 and set to run until December 31 2010.


About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.


Contact:

Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://reportsandreports.blogspot.com/
http://reportsandreports.proarticles.co.uk/
http://reportsnreports.wordpress.com/

Browse the complete Report on: Italy Pharmaceuticals and Healthcare Report Q4 2010

Browse All Business Monitor International Market Research Reports

In BMI's Q410 Pharmaceuticals & Healthcare Business Environment Ratings (BERs), the Western Europe region scored a total of 64.5 out of 100. The attractiveness of the region to pharmaceutical firms stems from the fact that its countries are key revenue sources for 'big pharma', particularly for companies selling high-end products, as per-capita spending is substantially above that of emerging markets. However, it is BMI's view that drug companies will face many challenges in Western Europe over the next decade, including pressures to reduce fiscal deficits, the patent cliff, added regulatory hurdles and increasingly scrupulous cost-effectiveness assessments of new drugs – all factors that will influence the risk and reward scores assigned to markets in the region.
In the Q410 BERs, Italy remains the least attractive Western European market of the ten surveyed. Despite being a large market, Italy is characterised by low levels of growth, largely a result of widespread price cuts and shaky levels of economic growth – which translate into insufficient funds for pharmaceutical expenditure, especially for innovative products. High levels of public debt, poor infrastructure and a lack of competitiveness indicate that the country will remain one of the region’s laggards over our forecast period. Additionally, pharmaceutical companies’ performance in the country – already hampered by counterfeiting and parallel imports – is also expected to be majorly impacted by the pending patent expiration ‘slope’.
In July 2010, Silvio Berlusconi's government won a confidence vote in the Senate over its EUR25bn (US$32bn) austerity package aimed at lowering the country's budget deficit from 5.3% of GDP in 2009 to 2.7% by 2012. The package incorporated a series of relatively minor changes introduced by parliament since the bill was originally presented at the end of May 2010.
Included in the package are a number of medicine cost-containment plans, as well as moves to speed the introduction of electronic prescribing, which in turn is expected to increase the prescription of generic medicines. Furthermore, a reduction in margins on sales of Class A reimbursed drugs will be split between pharmacists and manufacturers, with pharmacists losing 1.82% and drugmakers 1.83%. Furthermore, aiming to make annual savings of at least EUR600mn (US$768mn), the Italian agency for pharmaceuticals (AIFA) is to review the pharmaceutical expenditure of the various territorial regions in Italy in order to provide 'tools' that will direct the prescription of medicines towards lower-cost generic drugs.
Additionally, in a bid to contain rising healthcare costs and an increasing state drugs bill, the maximum reimbursement rate paid for generic medicines by the Italian national health service (SSN) will be based on the drugs' average prices in Europe as of 2011. The government claims pricing drugs in this manner will create cost savings of EUR600mn (US$768mn). Hitting generic drug producer revenues more immediately is a 12.5% reduction on retail prices of generics, an initiative implemented in June 2010 and set to run until December 31 2010.


About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000
micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.


Contact:

Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://reportsandreports.blogspot.com/
http://reportsandreports.proarticles.co.uk/
http://reportsnreports.wordpress.com/

Browse the complete Report on - Italy Agribusiness Report Q4 2010

Browse All Business Monitor International Market Research Reports

at http://www.reportsandreports.com/Publishers/business-monitor-international/

BMI View: Farmer protests have remained a fixture in Italian agriculture in 2010, highlighting some of the problems that refuse to go away. In particular, Italian farmers protested a government scheme to spare producers who exceed their quotas from the usual EU fines, saying it unfairly left out those who had already paid them. The reaction of the farmers, who said they have to produce large quantities of milk just to survive, shows quotas remain a sore point in the industry. The Italians can be expected to push for more reforms to the EU dairy industry going forward.
Key Views
- Poultry production is forecast to perform strongly. Lower feed prices combined with higher prices for poultry meat boosted margins, putting the industry on a healthy footing. In 2010 we expect expansion to continue and are forecasting growth of 3.9% to reach 1.19mn tonnes. - Beef production, as in most of Europe, is expected to continue its decline. We expect beef production to fall slightly from an estimated 1.06mn tonnes in 2009 to 1.05mn tonnes in 2010. Over our forecast period we expect a further decline to 1.02mn tonnes in 2014, down 3.90%.
- In 2010/11, reports of good growing conditions and excellent water availability mean we expect wheat production to come in at 7.48mn tonnes, up 18.1% year-on-year (y-o-y). BMI forecasts a rebound in corn production to 8.51mn tonnes.
- New data shows milk production declined lin 2009. Eurostat now estimates production at 10.42mn tonnes, down 0.7% year-on-year from the 10.49mn tonnes recorded in 2008. The drop came despite the raising of Italy's milk quota by 5% from April 2009. We expect a recovery, however, as prices rise again, with production to increase to 10.49mn tonnes in 2010.
- New Minister of Agriculture Giancarlo Galan has said he will push hard for legislation to protect traditional Italian foods from counterfeiters, after Italian farmers protested against imports of mozzarella from a German firm. The cheese had reportedly turned blue after exposure to the air - and was being sold under Italian sounding brand names. The legislation should help protect Italian cheeses from cheaper imports.
- Italy has expressed opposition to a proposed free trade deal between the EU and Mercosur. Although Italy was not among a group of 10 countries that the French government led in issuing a statement opposing the deal, the country is believed to have concerns over the consequences to its livestock industry.
- The debate over genetically modified (GM) crops took an interesting turn in Italy in 2009. A farmer attempted to test the muddy legal waters on biotech crops by planting a field of MON810 corn. In July, after he announced the plants were ready to harvest, 70 environmental activists invaded the farm and destroyed the crop. The future of GM in Italy remains difficult to predict, with strong lobbies both for and against the technology. While BMI believes that the prevailing wind remains against biotech crops, change is a possibility.


About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)


Contact:

Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

http://reportsandreports.blogspot.com/

http://reportsandreports.proarticles.co.uk/

http://reportsnreports.wordpress.com/